The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome

• Conditions: Polycystic Ovary Syndrome

• Registration Number: NCT02126592
• Lead Sponsor: RenJi Hospital

Brief Summary

Polycystic ovary syndrome (PCOS) is an endocrine disease in reproductive women. It is characterized by anovulation and hyperandrogenism. Most patients with PCOS have metabolic abnormalities such as dyslipidemia, insulin resistance and glucose abnormalities. Almost 60-80﹪PCOS patients are obesity which exacerbates IR and hyperandrogenism. Obese PCOS patients tend to be overeating suggests that impaired appetite regulation might be contribute to the pathophysiology of PCOS. Our study is trying to observe difference of incretin between PCOS and normal control to figure out whether change of incretin is involved in the pathophysiology of PCOS.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-03
• Status Verified: 2014-01
• Study First Submitted: 2014-01-21
• Primary Completion: 2014-04
• Study First Submitted QC: 2014-04-28
• Last Update Submitted: 2014-04-28
• Study First Posted: 2014-04-30
• Last Update Posted: 2014-04-30
• Study Completion: 2014-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• women at reproductive age
• women with PCOS and women without PCOS

Exclusion Criteria

• young women who had their menarche less than 3 years
• women older than 45 years old, Amenorrhea of menopause, hyperglycemia, hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia, dystrophy, gonitis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in incretin hormones secretion in PCOS patients.	up to 14 months

Trial Locations

Locations (1)

Renji Hospital; 🇨🇳 Shanghai, China